Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,213 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignant Neoplasm of Large Intestine Clear all
Completed Phase 2 Interventional Results available

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT00193219
View directory record Official record
Conditions
Colon Cancer
Interventions
Bevacizumab, Cetuximab, 5-fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
Evansville, Indiana • Louisville, Kentucky • Portland, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 15, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases

NCT01528878
View directory record Official record
Conditions
Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
Interventions
Stereotactic Radiosurgery using the CyberKnife System.
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

NCT00756548
View directory record Official record
Conditions
Colon Cancer
Interventions
BLI850, polyethylene glycol 3350 based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Anaheim, California • Orange, California • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 1Phase 2 Interventional

Improving Fecal Occult Blood Test Completion Rates Among Veterans

NCT01516489
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Stage 1, Stage 2
Behavioral
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
Male only
Enrollment
1,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 15, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

NCT01322815
View directory record Official record
Conditions
Colon Cancer
Interventions
chemotherapy and GI-4000, GI-4000
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 15, 2026, 5:23 PM EDT
Recruiting Phase 1 Interventional

A Study of PHN-012 in Patients With Advanced Solid Tumors

NCT07127874
View directory record Official record
Conditions
Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer, Advanced Solid Tumors
Interventions
PHN-012
Drug
Lead sponsor
Pheon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 5:23 PM EDT
Terminated No phase listed Observational Results available

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

NCT03765736
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Genetic Testing
Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

NCT01111604
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Not applicable Interventional

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

NCT01453452
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Pain, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Tucson, Arizona • Antioch, California • Fremont, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00003834
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
20
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 15, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

NCT00077233
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
77
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 15, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

NCT00314353
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Effectiveness of High Dose Vitamin D Supplementation in Stage III Colorectal Cancer

NCT02603757
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
cholecalciferol
Dietary Supplement
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

NCT00911170
View directory record Official record
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 15, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00449163
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Bevacizumab, Floxuridine, Irinotecan, Leucovorin
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Gemcitabine in Treating Patients With Advanced Colorectal Cancer

NCT00007943
View directory record Official record
Conditions
Colorectal Cancer
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

NCT00685568
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years to 14 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 15, 2026, 5:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials

NCT05655494
View directory record Official record
Conditions
Cancer
Interventions
Stand-alone Research Portal, Portal with Virtual Community Health Educator (vCHE)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations

NCT03100461
View directory record Official record
Conditions
Colorectal Cancer
Interventions
I2, Health Education
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 15, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions
PEPRR, Pep-Pal
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 5:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NCT05174169
View directory record Official record
Conditions
Stage III Colon Cancer
Interventions
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
Device · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1037
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative

NCT05064410
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Educational Intervention
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

NCT01652196
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
Biological · Drug · Other + 2 more
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 15, 2026, 5:23 PM EDT